NettetThe other 44 patients (41.9%) received PP as first-line therapy. ORRs of PP in patients with and without prior EGFR TKI therapy were 24.6% and 38.6%, respectively … NettetTel +86-571-87783642. Fax +86-571-87783318. Email [email protected]. Background: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is an effective treatment for advanced lung cancer harboring EGFR gene mutations, and has improved progression-free survival in several clinical trials.

First-Line Therapy in Patients With KRAS -Mutated Non–Small …

Nettet11. mai 2024 · At this moment the Line of Therapy Algorithm is supported for NSCLC, Melanoma and HNSCC indications Oncology indications. There are five common … Nettet21. mai 2024 · Given its high disease burden and high unmet need, lung cancer has emerged as a key target for treatment innovation. The last decade has been marked by … office 2021 professional plus activate

American Association for Cancer Research

Nettetfor 1 time siden · We see diarrhea, nausea, and vomiting. [Dosing] starts at 1.34 mg daily, but there is a lower dose at 0.89 mg. [It is given] 3 weeks on, 1 week off. Patients can … NettetResults. A total of 364 EGFR wild-type NSCLC patients who received second-line therapy were included in this analysis, of whom 108 received EGFR TKIs as second-line therapy, whereas 256 received chemotherapy as second-line therapy. Patient demographic data are shown in Table 1. Table 1 Demographic data of all patients. NettetIt was well tolerated in group B because of the mild adverse effects. Targeted therapy can be considered primarily for patients aged 80 years and older with advanced NSCLC … mycc.com log in